TY -的T1 -循环纤维细胞作为一种新的l to predict lung cancer progression after surgery? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01221-2021 SP - 2101221 AU - Henrot, Pauline AU - Beaufils, Fabien AU - Thumerel, Matthieu AU - Eyraud, Edmée AU - Boudoussier, Augustin AU - Begueret, Hugues AU - Maurat, Elise AU - Girodet, Pierre-Olivier AU - Marthan, Roger AU - Berger, Patrick AU - Dupin, Isabelle AU - Zysman, Maéva Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/09/09/13993003.01221-2021.abstract N2 - Lung cancer remains the leading cause of cancer death. In 2008, 2,206,771 new cases and 1,796,144 deaths were reported worldwide [1]. At diagnosis, approximately one third of the patients have a potentially resectable tumor that is confined to the chest without clinical evidence of mediastinal lymphadenopathy (clinical stages I and II). Nevertheless, even after complete surgical resection, the overall survival in such patients with early-stage disease remains disappointing. The 5-year survival rate even for patients with stage IA or IB non-small cell lung cancer (NSCLC) is 73% and 56%, respectively [2]. Besides, the 5-year risks of local or regional recurrence after surgery alone for non-small cell lung cancer for stages IA, IB, IIA, IIB, and IIIA are also high (16%, 23%, 37%, 39%, and 30%, respectively [3]). The 5-year survival of small cell lung cancer (SCLC) patients with early-stage resected disease (T1,2 N0M0) is roughly similar, around 50% [4]. Relapse of the disease at distant sites, despite complete removal of all macroscopic lesions, is the main cause of treatment failure [5–8]. The presence of micro-metastatic disease at resection is the likely reason for such relapse. However, the mechanisms involved in micro-metastases propagation remains to be clarified.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Henrot has nothing to disclose.Dr. Henrot reports non-financial support from Avad, outside the submitted work.Conflict of interest: Dr. Beaufils reports personal fees and non-financial support from Novartis, personal fees and non-financial support from Chiesi, personal fees and non-financial support from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Thumerel has nothing to disclose.Conflict of interest: Dr. Eyraud has nothing to disclose.Conflict of interest: Dr. Boudoussier has nothing to disclose.Conflict of interest: Dr. BEGUERET has nothing to disclose.Conflict of interest: Dr. Maurat has nothing to disclose.Conflict of interest: Dr. Girodet reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Chiesi, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees and non-financial support from Sanofi, outside the submitted work.Conflict of interest: Dr. Marthan has nothing to disclose.Conflict of interest: Dr. Berger reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Chiesi, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees and non-financial support from Sanofi, outside the submitted work.Conflict of interest: Dr. Dupin reports grants from Fondation Bordeaux Université, during the conduct of the study; In addition, Dr. Dupin has a patent (EP N°15152886.6 i.e. New compositions and methods of treating and/or preventing Chronic Obstructive Pulmonary Disease) pending.Conflict of interest: Dr. Zysman reports grants and personal fees from Astra Zeneca, personal fees from GSK, personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, outside the submitted work. ER -